EJMR
ERA'S JOURNAL OF MEDICAL RESEARCH
p-ISSN: 2348-9839, e-ISSN: 2394-5222 | www.ejmr.org

Volume 13 Issue 1
REVIEW ARTICLE

Lipid Nanoparticles as Enabling Platforms for mRNA Therapeutics: Biological Interfaces, Translational Progress, and Emerging Paradigms

Arvind Chansoria[1], Dilshad Ali Rizvi[2], Salma Khan[2]

Received on: 17-02-2026 Published on: 30-04-2026

ABSTRACT

Background: Messenger RNA (mRNA)-based therapies have fundamentally altered the landscape of modern drug development by enabling controlled, short-lived production of therapeutic proteins without permanent genomic modification. Despite clear mechanistic advantages, clinical deployment was historically constrained by rapid enzymatic degradation, inefficient cellular internalization, and activation of innate immune responses.

Objective: This review critically examines lipid nanoparticle (LNP) architecture, biological interactions, intracellular trafficking, immunological modulation, manufacturing constraints, and emerging technological innovations to provide a comprehensive understanding of the current state and future trajectory of LNP-mediated mRNA delivery.

Methodology: A comprehensive narrative review was conducted by systematically searching peer-reviewed literature from PubMed, Scopus, and Web of Science databases (2001–2025), supplemented by regulatory agency guidelines and authoritative clinical reports. Studies on LNP formulation, mRNA delivery, vaccine platforms, oncology applications, protein replacement, and genome editing were included.

Results: LNPs overcome the principal biological barriers to mRNA delivery through multi-component lipid architectures incorporating ionizable lipids, helper phospholipids, cholesterol, and PEG-conjugated lipids. The large-scale clinical validation achieved through COVID-19 mRNA vaccines has accelerated expansion into oncology, rare genetic disorders, protein supplementation, and in vivo genome editing. Emerging platforms integrate phytomedicine-derived adjuvants such as Withania somnifera and precision public health analytical frameworks to further advance LNP-based therapeutic delivery.

Conclusion: LNPs represent a mature yet rapidly evolving non-viral delivery platform. Continued advances in lipid chemistry, immune modulation, organ-specific targeting, and precision public health integration are expected to broaden the therapeutic spectrum of mRNA-based interventions, establishing LNP-mediated delivery as a cornerstone of next-generation precision medicine.

KEYWORDS: *Cancer vaccines, CRISPR delivery, Gene therapy, Lipid nanoparticles, Messenger RNA, mRNA therapeutics, Non-viral delivery, Nanomedicine, Precision public health.*

Era's Journal of Medical Research. 13(1);2026 [doi: 10.24041/ejmr.2026.8]

INTRODUCTION

Messenger RNA has transitioned from a transient cellular intermediary to a powerful therapeutic platform with broad clinical potential. In contrast to DNA-based approaches, mRNA operates exclusively within the cytoplasm, avoiding genomic integration and enabling precise temporal regulation of protein expression.[1] These inherent attributes make mRNA particularly attractive for indications requiring transient or repeated therapeutic protein production without permanent alteration of the host genome.

Despite these mechanistic advantages, unmodified mRNA is highly vulnerable to nuclease-mediated degradation and is rapidly eliminated from the systemic circulation. Its large molecular weight and strong negative charge further impede passive transmembrane transport. Consequently, clinical advancement of mRNA therapeutics has been tightly coupled to innovations in delivery vehicle technology.[2] Among the diverse non-viral platforms investigated to date, lipid nanoparticles have demonstrated superior capacity to protect mRNA cargo from degradation, promote efficient cellular entry, and facilitate intracellular release into the cytoplasm.

[1]Gajra Raja Medical College, Veer Savarkar Marg, Gwalior, Madhya Pradesh, India

[2]Department of Pharmacology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India

Corresponding Author: Arvind Chansoria

Email: dr.arvindchansoria@gmail.com

How to cite: Chansoria1 A, Rizvi DA, Khan S. Lipid Nanoparticles as Enabling Platforms for mRNA Therapeutics: Biological Interfaces, Translational Progress, and Emerging Paradigms. Era J Med Res. 2026;13(1):36-42.

The global deployment of LNP-formulated mRNA vaccines during the COVID-19 pandemic marked an inflection point in modern pharmacology, providing unprecedented clinical validation of this delivery platform at population scale.[3] Since this milestone, research focus has expanded toward refining organ-specific targeting, attenuating immune-related adverse effects, and enabling safe administration in chronic disease settings.

Broader precision public health frameworks are increasingly being adopted to deploy mRNA therapeutics at the population level in an equitable and evidence-based manner.[35]

This review provides a structured critical analysis of the biological rationale, molecular architecture, physicochemical determinants, immunological interactions, and clinical applications of LNP-mediated mRNA delivery, with particular attention to emerging paradigms that are shaping the future of this transformative therapeutic modality.

Review of Literature

Biological Barriers to mRNA Delivery

Effective systemic delivery remains the foremost biological challenge for mRNA therapeutics. Unprotected mRNA administered intravenously is rapidly degraded by circulating ribonucleases and eliminated by phagocytic cells before reaching intended target tissues.[4] Furthermore, even when cellular internalization is achieved, the majority of mRNA cargo remains sequestered within endosomal compartments, unable to access the cytosolic ribosomal translation apparatus.[16] These dual barriers — extracellular degradation and intracellular entrapment — represent the principal pharmacokinetic obstacles that LNP formulation strategies must overcome.

Compared with viral delivery vectors, LNPs offer substantial practical and safety-related advantages: absent replication competence, substantially reduced immunogenicity, simpler large-scale manufacturing, and rapid adaptability to new therapeutic sequences.[6] These features collectively position LNPs as an especially flexible platform for personalized medicine applications and rapid-response infectious disease countermeasures.

Molecular Architecture of Lipid Nanoparticles

Lonizable lipids

Ionizable lipids constitute the functional core of contemporary LNP formulations. These molecules are engineered to remain predominantly uncharged at physiological pH (7.4), thereby limiting undesirable interactions with serum proteins and off-target cell membranes.7 Under the acidic conditions encountered during LNP formulation or within endosomal compartments (pH 5.0–6.5), ionizable lipids acquire a net positive charge, enabling strong electrostatic complexation with negatively charged mRNA and promoting membrane-destabilizing interactions with anionic endosomal lipids.

Modern lipid engineering emphasizes biodegradability, frequently incorporating ester linkages or disulfide bonds into the hydrophobic domain. These chemical features enable enzymatic or reductive cleavage in-vivo, reducing lipid accumulation in organs such as liver and spleen and thereby substantially improving the long-term safety profile.[8]

Helper Lipids and Cholesterol

Phospholipid helper components — predominantly distearoylphosphatidylcholine (DSPC) and dioleoylphosphatidyl ethanolamine (DOPE) — enhance nanoparticle structural integrity and promote membrane fusion with endosomal bilayers. Cholesterol contributes to membrane fluidity regulation and modulates nanoparticle rigidity; variations in cholesterol content significantly influence intracellular trafficking efficiency and endosomal escape rates.[9]

Surface-Stabilizing PEG-Lipids and Alternatives

Polyethylene glycol (PEG)-conjugated lipids are incorporated as surface stabilizers to improve colloidal stability and extend systemic circulation half-life through steric inhibition of opsonin adsorption.[10] However, repeated LNP administration has been associated with anti-PEG antibody formation, potentially leading to accelerated blood clearance and hypersensitivity responses.[11] In response, alternative surface modification strategies employing zwitterionic lipids and polysarcosine-based coatings are under active development as immunologically inert PEG substitutes.

Physicochemical Determinants of LNP Performance

The in-vivo pharmacological behavior of lipid nanoparticles is governed by a constellation of physicochemical parameters including particle diameter, surface zeta potential, lipid molar composition, and internal liquid-crystalline organization.[12] LNPs with diameters in the 70–100 nm range achieve an optimal balance between prolonged systemic circulation and efficient endocytic cellular uptake.[13] Emerging evidence underscores the importance of internal nanostructure: non-lamellar, inverted hexagonal lipid arrangements enhance endosomal membrane disruption efficiency and cytosolic mRNA delivery compared with conventional lamellar organizations.[14]

Intracellular Trafficking and Endosomal Escape

Cellular Entry Mechanisms

LNPs are internalized predominantly via endocytic pathways, including clathrin-dependent endocytosis, caveolae-mediated uptake, and macropinocytosis.[15] The relative contribution of each pathway is cell-type dependent and is influenced by LNP surface characteristics, lipid composition, and the degree of apolipoprotein adsorption onto the particle surface following systemic administration.

Endosomal Escape — The Critical Rate-Limiting Step

Endosomal escape represents the principal bottleneck in mRNA delivery; quantitative fluorescence imaging studies have demonstrated that fewer than 2% of endocytosed LNP particles successfully release their mRNA cargo into the cytoplasm.[16] Acidification of maturing endosomes triggers protonation of ionizable lipids, generating a positive charge that promotes formation of ion pairs with anionic endosomal membrane phospholipids, ultimately destabilizing the endosomal bilayer and enabling cytosolic mRNA release.[17] Enhancing endosomal escape efficiency remains a central objective in formulation optimization, as even modest improvements yield proportionally large gains in translated protein output.[18]

Immunological Interactions and Modulation

Both the mRNA payload and the lipid excipients of LNPs activate innate immune surveillance pathways. Pattern recognition receptors — including endosomal Toll-like receptors (TLR3, TLR7, TLR8) and cytosolic RIG-I-like receptors — detect unmodified exogenous RNA, triggering type I interferon secretion and downstream inflammatory cascades that impair translation and cause systemic reactogenicity.[19]

Incorporation of chemically modified nucleosides — most significantly N1-methylpseudouridine (m1Ψ) — substantially reduces innate immune recognition while simultaneously enhancing ribosomal translation efficiency, thereby achieving a superior therapeutic window.[20] Lipid-intrinsic inflammatory properties must also be carefully managed through composition optimization, as certain ionizable lipids can independently activate complement pathways and elicit injection-site reactogenicity.[21]

The relationship between LNP-mediated mRNA delivery and broader oncological immunotherapy parallels the

immunomodulatory framework demonstrated for phytochemical agents such as Withania somnifera, whose bioactive withanolides modulate NF-κB signaling, NK cell activity, and cytokine profiles through mechanistically analogous immune pathway interactions.33 Understanding these intersecting immunological mechanisms may inform the rational design of combination strategies incorporating natural immunomodulatory adjuvants within LNP formulations.

Therapeutic Applications of LNP-mRNA Systems

Infectious Disease Vaccines

LNP-formulated mRNA vaccines for COVID-19 (BNT162b2 and mRNA-1273) provided definitive clinical proof of concept for this platform, demonstrating 90–95% protective efficacy in pivotal Phase 3 trials.[22] This clinical validation has catalyzed parallel development of LNP-based mRNA vaccines targeting influenza, respiratory syncytial virus, cytomegalovirus, HIV, and pandemic-preparedness pathogens. Ongoing programs aim to improve thermostability, reduce dosing requirements, and extend shelf life at ambient temperature.

The synergy between advanced molecular diagnostic tools and mRNA vaccine platforms is exemplified by cervical cancer prevention, where high-sensitivity primary HPV DNA testing (achieving CIN2+ sensitivity of 95.93%) provides precise epidemiological risk stratification that directly informs population-targeted HPV vaccination deployment strategies.[34] This integrated diagnostic-therapeutic paradigm represents an important model for precision vaccine delivery in oncology prevention.

Oncology: Personalized Cancer Vaccines and Immunotherapy

In oncology, LNPs enable delivery of mRNA encoding tumor-associated antigens, patient-specific neoantigens, immunostimulatory cytokines, and immune checkpoint modulators. Personalized neoantigen cancer vaccines tailored to the individual mutational landscape of each patient's tumor represent one of the most transformative potential applications of LNP technology.[23] Emerging complementary approaches incorporating nanotechnology-based formulations of plant-derived bioactive compounds, including with anolides from Withania somnifera, further enhance the stability, bioavailability, and cancer-cell-specific delivery of therapeutic agents alongside LNP-based strategies.[33] Withaferin A, in particular, has demonstrated direct cytotoxic effects in lung, breast, prostate, colon, and leukemia cell lines through induction of apoptosis, cell cycle arrest, and inhibition of NF-κB and mTOR signaling pathways, supporting its potential as an adjuvant within integrated LNP-based cancer treatment platforms.

Protein Replacement Therapy

mRNA-mediated transient therapeutic protein production provides a clinically viable alternative to conventional enzyme replacement therapy (ERT) for rare inherited metabolic disorders including methylmalonic acidemia, propionic acidemia, and alpha-1 antitrypsin deficiency. LNPs support repeat hepatic dosing with controlled protein expression kinetics, without the immunogenic risks or high manufacturing costs associated with recombinant protein biologics.[24]

In-vivo Genome Editing

LNP-based delivery of CRISPR-Cas9 or base editor mRNA enables precisely timed, transient genome modification with substantially reduced risk of off-target editing compared with viral vectors that provide sustained nuclease expression. This platform is increasingly preferred for therapeutic in vivo gene editing, as demonstrated by the clinical success of LNP-delivered CRISPR therapy for transthyretin amyloidosis.[25]

Safety and Toxicological Profile

Available clinical data from vaccine and early therapeutic programs indicate acceptable short-term safety profiles for LNP-mRNA systems in human subjects. Nonetheless, potential long-term concerns warrant continued post-marketing surveillance, including hepatic lipid accumulation following repeated high-dose administration, complement activation-related pseudoallergy (CARPA), and vaccine-unrelated systemic inflammatory responses.[26]

The development of rapidly biodegradable ionizable lipids incorporating enzymatically or reductively cleavable linkers, combined with optimized dosing interval schedules, represents the primary formulation strategy for improving long-term tolerability.[27] Rigorous dose-response characterization and species-appropriate preclinical toxicology models remain essential to de-risk LNP therapeutic programs prior to first-in-human administration.

Manufacturing and Regulatory Landscape

Microfluidic mixing technology enables scalable, reproducible LNP production with precise particle size distribution control and high encapsulation efficiency at commercial scale.[28] Regulatory guidance from the European Medicines Agency (EMA), FDA, and international harmonization bodies increasingly demands comprehensive physicochemical characterization, biodistribution profiling, and long-term stability data, particularly for novel non-vaccine LNP therapeutic applications.[29]

Emerging Strategies: Targeting, Alternative Routes, and AI Integration

Tissue-selective LNP delivery is achievable through selective organ targeting (SORT) technology, in which modulation of the molar fraction of additional permanently charged lipids directs organ tropism toward lung, spleen, or specific hepatic cell populations.[30] Pulmonary and intranasal routes of administration offer additional organ-specificity while reducing systemic lipid exposure.[31] Artificial intelligence and machine learning algorithms are increasingly applied to accelerate de novo ionizable lipid discovery, optimize multi-component formulation ratios, and predict in vivo organ tropism from structural descriptors.[32]

Precision public health frameworks — integrating genomic epidemiology, digital surveillance, geospatial analytics, and targeted population health interventions — are emerging as essential infrastructure for the equitable deployment of LNP-based mRNA therapeutics at scale.[35] These frameworks enable stratification of at-risk populations, identification of implementation gaps, and optimization of delivery logistics within resource-constrained healthcare systems.

AIMS AND OBJECTIVES

Primary Aim

To provide a comprehensive critical review of lipid nanoparticles as enabling delivery platforms for mRNA therapeutics, encompassing their biological, physicochemical, immunological, and clinical dimensions, with integration of emerging data on precision medicine tools and natural adjuvants.

Specific Objectives

- To delineate the molecular architecture and physicochemical characteristics of contemporary LNP formulations and relate these parameters to in vivo delivery performance.
- To critically analyze the intracellular trafficking pathways of LNPs, with particular emphasis on endosomal escape efficiency as the primary determinant of cytosolic mRNA delivery.
- To evaluate the immunological interactions of LNP-mRNA systems with the innate and adaptive immune systems and review chemical and formulation strategies for immune modulation.
- To systematically review the therapeutic applications of LNP-mRNA platforms across infectious disease vaccination, oncology, protein replacement therapy, and in-vivo genome editing.
- To examine the role of emerging tools — including AI-assisted lipid design, phytomedicine-derived immunomodulators such as Withania somnifera, HPV molecular diagnostics for cancer prevention, and precision public health analytics — in broadening the LNP therapeutic ecosystem.
- To identify current safety, manufacturing, and regulatory challenges and outline translational pathways toward next-generation LNP-mRNA medicines.

METHODOLOGY

Study Design

This study employs a comprehensive narrative review design, systematically synthesizing published peer-reviewed literature, regulatory guidance documents, and authoritative clinical reports pertaining to lipid nanoparticle-mediated mRNA delivery. A narrative approach was selected given the breadth of the topic, the need to integrate mechanistic, translational, and clinical perspectives, and the rapidly evolving nature of the evidence base.

Literature Search Strategy

A systematic literature search was conducted across three major biomedical databases:

- PubMed/MEDLINE (National Library of Medicine)
- Scopus (Elsevier)
- Web of Science (Clarivate Analytics)

Search terms were constructed using Boolean operators combining the following Medical Subject Headings (MeSH) and free-text keywords: lipid nanoparticles, LNP, mRNA therapeutics, messenger RNA delivery, non-viral vectors, ionizable lipids, endosomal escape, mRNA vaccines, COVID-19 mRNA, CRISPR delivery, nanoparticle pharmacokinetics, cancer nanomedicine, Withania somnifera anticancer, HPV DNA testing, precision public health, and AI drug formulation. The search was restricted to English-language publications from January 2001 through June 2025. Reference lists of included articles were hand-searched for additional relevant citations.

Inclusion and Exclusion Criteria

Inclusion Criteria

- Original research articles, systematic reviews, meta-analyses, and narrative review articles addressing LNP composition, formulation, pharmacokinetics, or therapeutic applications.
- Clinical trials and translational studies reporting in vivo or human data on LNP-mRNA systems.
- Regulatory agency guidelines from FDA, EMA, and WHO specifically addressing nanoparticle therapeutics and mRNA medicines.
- Publications on phytomedicine-based adjuvants (Withania somnifera), molecular cervical cancer diagnostics (HPV DNA testing), and precision public health frameworks insofar as they interface with mRNA therapeutic deployment.

Exclusion Criteria

- Studies exclusively addressing viral vector-mediated gene delivery without comparative or contextual LNP data.
- Conference abstracts without peer-reviewed full-text publication.
- Non-English language publications.
- Studies with insufficient methodological detail to permit quality assessment.

Data Extraction and Synthesis

Relevant data were extracted from included publications covering: (1) LNP molecular composition and architectural features; (2) physicochemical characterization parameters; (3) cellular uptake and intracellular trafficking mechanisms; (4) immunological response profiles; (5) therapeutic application data across disease categories; (6) manufacturing and regulatory considerations; and (7) emerging technological developments. Findings were organized thematically and synthesized using narrative integration, with particular emphasis on identifying converging evidence, unresolved controversies, and gaps in the translational evidence base.

Quality Assessment

The methodological quality of included experimental studies was evaluated informally, with priority given to studies employing controlled experimental designs, validated analytical methods, and appropriate statistical approaches. For clinical data, only trials registered with recognized clinical trial registries (ClinicalTrials.gov, EudraCT) were included. Systematic reviews were evaluated using the PRISMA reporting framework where applicable.

RESULTS

LNP Formulation Architecture: A Multi-Component System

The literature search identified strong convergent evidence that optimal LNP performance requires precise stoichiometric optimization of four principal components: ionizable lipid (35–50 mol%), helper phospholipid (10–20 mol%), cholesterol (30–40 mol%), and PEG-lipid (1.5–3 mol%). The ionizable lipid DLin-MC3-DMA and its successor SM-102 (used in mRNA-1273) and ALC-0315 (used in BNT162b2) represent the current gold standard for hepatic mRNA delivery, achieving up to 90% hepatocyte transfection efficiency in preclinical models.

Emerging biodegradable ionizable lipids incorporating ester linkages demonstrate 5–10-fold reductions in hepatic lipid accumulation at equivalent mRNA expression levels compared with non-degradable predecessors, significantly improving preclinical safety margins.[8]

Endosomal Escape: The Central Pharmacological Bottleneck

Quantitative imaging studies consistently demonstrate that only 1–2% of endocytosed LNP cargo successfully escapes endosomal sequestration to reach the cytoplasm.[16] This represents the primary rate-limiting step governing translational output. The

ionizable lipid pKa — specifically values between 6.2 and 6.8 — is the single most predictive physicochemical parameter for endosomal escape efficiency and corresponding in vivo protein expression level.[18] Lipid formulations generating non-lamellar (inverted hexagonal phase) nanostructures upon endosomal acidification demonstrate up to 4-fold improvements in cytosolic mRNA delivery efficiency.[14]

Immune Modulation: Balancing Efficacy and Reactogenicity

Incorporation of N1-methylpseudouridine (m1Ψ) into mRNA constructs reduces TLR7/8-mediated type I interferon induction by greater than 90% while simultaneously increasing translational efficiency by up to 10-fold compared with unmodified uridine-containing mRNA.[20] The lipid-intrinsic inflammatory properties of LNP components, particularly the ionizable lipid, contribute independently to injection-site and systemic reactogenicity and must be optimized in parallel with mRNA nucleoside modification strategies.[21]

The immunomodulatory pharmacology of LNPs shares mechanistic convergence with the actions of Withania somnifera-derived withanolides, which modulate NF-κB, p38/MAPK, and Nrf2/HO-1 signaling pathways to produce context-dependent immunostimulatory or anti-inflammatory effects.[33] These overlapping pathway interactions suggest potential additive or synergistic effects when phytomedicine-derived compounds are co-formulated or co-administered with LNP-based immunotherapeutic mRNA constructs.

Clinical Evidence: COVID-19 Vaccines and Emerging Therapeutic Programs

The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) LNP-mRNA COVID-19 vaccines achieved 90–95% protective efficacy against symptomatic disease in pivotal Phase 3 clinical trials enrolling over 30,000 participants each, establishing the largest clinical validation dataset ever generated for a non-viral gene delivery platform.[22] Post-authorization safety surveillance across hundreds of millions of administered doses confirmed an acceptable benefit-risk profile, with rare cases of myocarditis in young males as the primary safety signal of concern.

Beyond infectious disease, ongoing Phase 1/2 clinical trials are evaluating LNP-mRNA platforms for personalized neoantigen cancer vaccines, OTC deficiency protein replacement, and TTR amyloidosis CRISPR gene editing.[23-25] Early-phase data consistently demonstrate dose-dependent protein expression and acceptable tolerability profiles.

Oncological Integration: Phytomedicine, Molecular Diagnostics, and LNP Synergies

The oncological deployment of LNP-mRNA systems benefits from parallel advances in cancer risk stratification and complementary therapeutic modalities. Primary HPV DNA testing achieves significantly higher sensitivity for cervical precancer (CIN2+ sensitivity: 95.93%) compared with cytology alone, enabling precise identification of women at highest risk who represent the optimal target population for therapeutic mRNA vaccine interventions.34 The shift from co-testing to primary HPV testing as the gold standard screening paradigm, now endorsed by WHO, ACS, and ASCCP, provides the epidemiological precision needed to efficiently deploy LNP-based cervical cancer therapeutic vaccines in high-burden settings.

Withania somnifera bioactive constituents — particularly withaferin A — demonstrate multi-cancer cytotoxic activity mediated by apoptosis induction, cell cycle arrest (G1, G2/M), and inhibition of oncogenic NF-κB and mTOR/STAT3 signaling.[33] Nanotechnology-based delivery of withanolides has been shown to enhance their stability, bioavailability, and cancer-cell-specific delivery, providing a directly analogous nanotechnology convergence point with LNP-mRNA cancer therapeutic platforms. Combined LNP strategies co-delivering mRNA immunostimulatory payloads with withanolide adjuvants represent a scientifically rational avenue for future investigation.

Precision Public Health Integration

Systematic umbrella review evidence demonstrates that precision public health frameworks — incorporating genomic epidemiology, digital health surveillance, geospatial analytics, and machine learning-based risk stratification — substantially enhance the efficiency and equity of population-level preventive interventions.[35] Applied to LNP-mRNA therapeutic deployment, these analytical frameworks enable identification of highest-risk subpopulations, optimization of geographic delivery logistics, real-time pharmacovigilance signal detection, and equitable resource allocation across socioeconomic strata.

A persistent challenge identified across the precision public health literature is the implementation gap between technically superior interventions validated in high-income settings and their operational feasibility in low- and middle-income country (LMIC) health systems.35 Analogously, 60% of cervical cancer cases in India are diagnosed at advanced stage, reflecting a critical failure in early detection infrastructure that precision public health approaches — combined with LNP-based therapeutic vaccines — could systematically address.[34]

Emerging Manufacturing and AI-Assisted Formulation

AI and machine learning approaches applied to LNP formulation design have reduced the time from lipid synthesis to in-vitro potency screening by more than 10-fold compared with conventional design-of-experiment approaches.[32] Microfluidic manufacturing platforms now enable continuous-flow LNP production at clinical GMP scale with coefficient of variation <5% for particle size and >90% encapsulation efficiency, meeting regulatory specification requirements.[28]

DISCUSSION

The collective evidence synthesized in this review confirms that lipid nanoparticles have achieved the transition from experimental laboratory construct to clinically validated therapeutic platform with proven population-scale applicability. The mechanistic convergence of protective mRNA encapsulation, efficient cellular entry, pH-responsive endosomal escape, and nucleoside-modified immune evasion constitutes a formulation framework sufficiently robust to support a broad spectrum of therapeutic applications beyond infectious disease prevention.

The translation of LNP technology from COVID-19 vaccines to oncology represents arguably the most significant expansion opportunity.[23] Personalized neoantigen cancer vaccines, enabled by rapid tumor genomic sequencing and scalable mRNA synthesis, offer the prospect of tumor-specific cytotoxic T-cell responses tailored to the individual mutational landscape of each patient. The therapeutic complementarity between LNP-delivered immunostimulatory mRNA and phytomedicine-derived immunomodulators such as withaferin A — which independently activates NK cells, suppresses NF-κB, and induces cancer-cell apoptosis33— suggests that rationalized combination strategies warrant systematic preclinical evaluation in relevant tumor models.

An important dimension frequently underexplored in LNP literature is the role of precision cancer screening in determining the target populations most likely to benefit from therapeutic mRNA interventions. As demonstrated by the paradigm shift toward primary HPV DNA testing,[34] molecular diagnostic precision enables stratification of disease risk with sufficient granularity to guide targeted vaccine deployment decisions. Women testing positive for HPV16 or HPV18 face substantially higher immediate cancer risk and represent the highest-priority population for therapeutic HPV mRNA vaccine candidacy. This diagnostic-therapeutic integration model provides a transferable template for LNP-based mRNA therapeutic program design across oncological indications.

The long-term safety of repeated LNP administration remains an area requiring continued vigilance. While single-dose and two-dose vaccine regimens have demonstrated acceptable safety profiles across hundreds of millions of recipients, the pharmaco-toxicological implications of monthly or quarterly dosing — as would be required for protein replacement or genome editing maintenance indications — remain less well characterized.26,27 Development of fully biodegradable ionizable lipid chemistries with rapid hepatic clearance is the most promising strategy for addressing this concern without sacrificing delivery performance.

Precision public health frameworks provide the overarching population health infrastructure required for equitable LNP therapeutic deployment.[35] The literature consistently identifies data quality, algorithmic bias, and health system capacity as the principal implementation barriers — concerns that mirror the HPV-screening implementation challenges documented in LMIC settings.[34] Successful integration of LNP-mRNA therapeutics into population health programs will require governance structures that ensure privacy-preserving data use, transparent algorithmic decision-making, and equity-centered resource allocation.

The integration of artificial intelligence into both LNP formulation discovery and precision public health analytics represents a convergent technological force that may substantially accelerate the identification of optimal lipid structures, prediction of organ tropism, and identification of highest-risk patient subgroups — thereby compressing the translational timeline from laboratory discovery to population-level therapeutic impact.[32,35]

CONCLUSION

Lipid nanoparticles have accomplished a fundamental transformation of mRNA from an inherently fragile cellular intermediate into a clinically deployable therapeutic modality with proven efficacy at population scale. The multi-component LNP architecture — optimized across ionizable lipid chemistry, nucleoside modification, and surface engineering — overcomes the principal biological barriers of nuclease degradation, cellular impermeability, and endosomal entrapment that historically precluded clinical mRNA application.

The clinical horizon for LNP-mRNA systems extends well beyond pandemic vaccine response. Personalized oncology vaccines, hepatic protein replacement, and CRISPR-mediated in-vivo gene correction represent near-term clinical translation opportunities, while pulmonary mRNA delivery, AI-designed ionizable lipids, and phytomedicine-conjugated LNP constructs define the intermediate-term frontier. The established safety and efficacy of nanotechnology-based formulations of immunomodulatory natural products such as Withania somnifera,[33] provides scientific rationale for their rational integration into next-generation LNP-based cancer immunotherapy platforms.

Equitable realization of LNP-mRNA therapeutic potential requires parallel investment in precision public health infrastructure capable of identifying at-risk populations, managing implementation at scale, and ensuring that therapeutic benefits reach resource-limited communities.35 The successful adoption of primary HPV DNA testing as the gold standard for cervical cancer screening34 illustrates how molecular diagnostic precision, clinical guideline evolution, and equity-focused implementation can collectively optimize the population-level impact of evidence-based biomedical innovations.

As mechanistic understanding of nanoparticle-host interactions deepens and translational evidence accumulates across therapeutic indications, LNP-mediated mRNA delivery is well positioned to become a foundational modality of precision medicine — capable of addressing the spectrum of disease from pandemic preparedness to individualized cancer immunotherapy with an unprecedented combination of adaptability, scalability, and clinical performance.

REFERENCES

1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780.
2. Pardi N, Hogan MJ, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
3. Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318–324.
4. Kauffman KJ, Webber MJ, Anderson DG. Materials for nonviral intracellular delivery of messenger RNA therapeutics. J Control Release. 2016;240:227–234.
5. Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.
6. Ginn SL, Amaya AK, Alexander IE. Gene therapy clinical trials worldwide. J Gene Med. 2018;20(5):e3015.
7. Semple SC. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–176.
8. Maier MA. Biodegradable lipids enabling RNA delivery. Mol Ther. 2013;21(8):1570–1578.
9. Buschmann MD. Nanomaterial delivery systems for mRNA vaccines. Vaccines. 2021;9(1):65.
10. Knop K. Poly(ethylene glycol) in drug delivery. Angew Chem Int Ed. 2010;49(36):6288–6308.
11. Ishida T, Kiwada H. Anti-PEG antibodies — the accelerated blood clearance (ABC) phenomenon. J Control Release. 2008;131(1):1–7.
12. Mitchell MJ. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124.
13. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467–1475.
14. Kulkarni JA. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano. 2018;12(5):4787–4795.
15. Sahay G. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182–195.
16. Gilleron J. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638–646.

17. Hafez IM, Cullis PR. Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev. 2001;47(2–3):139–148.

18. Jayaraman M. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed. 2012;51(34):8529–8533.

19. Karikó K. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175.

20. Karikó K. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840.

21. Ndeupen S. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479.

22. Polack FP. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.

23. Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–1360.

24. An D. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548–3558.

25. Gillmore JD. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502.

26. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216(2–3):106–121.

27. Sedic M. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet Pathol. 2018;55(3):341–354. Original reference: Sedic M, et al. Mol Ther. 2018;26:2714–2725.

28. Zhigaltsev IV. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir. 2012;28(7):3633–3640.

29. European Medicines Agency (EMA). Guideline on the quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials — Reflection Paper on mRNA-based medicinal products. 2023.

30. Cheng Q. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313–320.

31. Maugeri M. Engineered nanoparticles for drug delivery in cancer therapy. Adv Drug Deliv Rev. 2019;151–152:19–90.

32. Anderson DG. Combinatorial development of lipid nanoparticles for RNA delivery. Acc Chem Res. 2020;53(10):2100–2112.

33. Akram M, Khan FA, Patel VR, et al. Exploring Withania Somnifera: A Novel Immunomodulatory and Anticancer Pharmaceutical Agent. Era J Med Res. 2025;12(3):143–148.

34. Garg N, Srivastava S. Incorporation of HPV DNA Testing alongside Pap smears Increases Sensitivity for Cervical Cancer Screening. Era J Med Res. 2025;12(3):171–180.

35. Khan MSA. Precision Public Health: Future Directions — A Structured Umbrella Review. Era J Med Res. 2025;12(3):122–124.

Orcid ID:

Arvind Chansoria - https://orcid.org/0009-0006-5370-9031

Dilshad Ali Rizvi - https://orcid.org/0000-0002-8056-7896

Salma Khan - https://orcid.org/0000-0001-7511-6866